中国生物制药： LM-299对外授权合作顺利，3亿美元里程碑将于近期收款

Group 1 - The core point of the article is that China Biologic Products (01177.HK) is set to receive a milestone payment of $300 million related to the technology transfer of LM-299, a PD-1/VEGF dual antibody, from Merck [1] - The technology transfer for LM-299 was completed in July 2023, and the payment is expected to be confirmed in the third quarter of 2023 [1] - Merck has indicated that the LM-299 project is progressing as planned, as stated during their second-quarter earnings call [1]